Psoriasis Drug Market to Reach $66.90 Billion by 2035

Psoriasis drug market was valued at $27.50 billion in 2025 and is projected to reach $66.90 billion by 2035, growing at a CAGR of 10.37% during the forecast period (2026–2035). The increasing global burden of chronic autoimmune diseases and rising adoption of biologics are significantly driving market growth. According to the World Health Organization, psoriasis affects more than 125 million people globally, representing a substantial patient pool requiring long-term treatment. The disease is associated with systemic complications such as cardiovascular disorders and psoriatic arthritis, further increasing treatment demand. Biologics and targeted therapies are increasingly being adopted due to their superior efficacy in moderate-to-severe cases, while topical therapies continue to dominate mild cases, supporting balanced growth across treatment categories.

Browse the full report description of “Psoriasis Drug Market Size, Share & Trends Analysis Report, By Drug Class (Biologics, Small Molecules, Topical Therapies, Systemic Non-Biologics), By Disease Type (Plaque Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis), By Severity Level (Mild Psoriasis, Moderate Psoriasis, Severe Psoriasis), By End-User (Hospitals, Dermatology Clinics, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/psoriasis-drugs-market

Europe Autoimmune Disease Burden and Biologic Therapy Adoption

In Europe, the increasing burden of autoimmune diseases and rising healthcare investments are driving demand for advanced psoriasis treatments. According to the European Commission, healthcare expenditure across EU countries continues to grow steadily, supporting access to advanced biologic therapies. Additionally, improved reimbursement policies and early diagnosis programs are accelerating treatment uptake. The increasing adoption of IL-17 and IL-23 inhibitors is transforming treatment protocols, as these therapies provide targeted immune modulation with improved clinical outcomes. Hospitals and dermatology clinics are witnessing higher patient inflow for chronic disease management, further strengthening demand for psoriasis drugs across the region.

US Healthcare Expansion and FDA Approvals Supporting Market Growth

In the United States, strong regulatory support and continuous drug approvals are significantly contributing to market expansion. According to the U.S. Food and Drug Administration, the number of approvals for biologics and specialty drugs has increased in recent years, supporting innovation in autoimmune disease treatment. The growing prevalence of chronic inflammatory conditions and high healthcare spending are driving demand for advanced therapies. Additionally, increasing awareness among patients and physicians regarding biologic treatments is accelerating adoption. The presence of leading pharmaceutical companies and ongoing clinical research are further strengthening the psoriasis drug market in North America.

Key Leaders Transforming the Psoriasis Drug Market

The key players in the psoriasis drug market include AbbVie Inc., Johnson & Johnson, Novartis AG, Amgen Inc., and Eli Lilly and Company, among others. These companies are driving innovation through the development of biologics targeting IL-17, IL-23, and TNF-alpha pathways, enhancing treatment efficacy and patient outcomes. Strategic investments in research and development, along with expansion of global distribution networks, are enabling companies to strengthen their market position and meet increasing demand.

• In February 2026, Eli Lilly and Company reported positive topline results from the Phase 3b TOGETHER-PsO trial, demonstrating that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) achieved superior skin clearance and weight loss compared to Taltz alone. The study highlights a shift toward integrated treatment approaches for managing psoriasis and associated metabolic conditions.
• In September 2025, Johnson & Johnson received approval from the U.S. Food and Drug Administration for Tremfya (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis in patients aged 6 years and older. This approval expands treatment options in pediatric autoimmune conditions and strengthens the company’s position in IL-23 inhibitor therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Class
• Disease Type
• Severity Level
• End-User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – AbbVie Inc., Johnson & Johnson, Novartis AG, Amgen Inc., Eli Lilly and Company, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Psoriasis Drug Market Report Segment

By Drug Class

• Biologics
• Small Molecules
• Topical Therapies
• Systemic Non-Biologics

By Disease Type

• Plaque Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
• Psoriatic Arthritis

By Severity Level

• Mild Psoriasis
• Moderate Psoriasis
• Severe Psoriasis

By End-User

• Hospitals
• Dermatology Clinics
• Homecare Settings

Global Psoriasis Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/psoriasis-drugs-market